AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29575737 — intervention group
Group type: COMPARATOR
Intervention: Palpation-guided intraarticular glucocorticoid injections
Number of subjects: 0
Study 29575737 — intervention group
Group type: EXPERIMENTAL
Intervention: Injecting clinically swollen joints without power Doppler (PD) activity on ultrasound
Number of subjects: 0
Study 27561366 — intervention group
Group type: EXPERIMENTAL
Intervention: DTCP LUTS/BPH tool (Group B)
Number of subjects: 278
Study 27561366 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment without DTCP (Group A)
Number of subjects: 278
Study 25327602 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 g of plant sterol esters a day (treatment group, n = 30)
Number of subjects: 59
Study 25327602 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 29)
Number of subjects: 59
Study 23535803 — intervention group
Group type: EXPERIMENTAL
Intervention: CKC exercise
Number of subjects: 39
Study 23535803 — intervention group
Group type: EXPERIMENTAL
Intervention: OKC exercise
Number of subjects: 39
Study 23535803 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 39
Study 19758267 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose tacrolimus
Number of subjects: 0
Study 19758267 — intervention group
Group type: COMPARATOR
Intervention: Low-dose cyclosporine
Number of subjects: 0
Study 19758267 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g MMF plus low-dose tacrolimus
Number of subjects: 0
Study 19083666 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy (twice weekly from partners from 20 weeks gestation until the end of pregnancy)
Number of subjects: 47
Study 19083666 — intervention group
Group type: COMPARATOR
Intervention: Control group (no massage therapy)
Number of subjects: 47
Study 17217216 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (400mg 3 times daily, as coated, sustained release tablets)
Number of subjects: 29
Study 17217216 — intervention group
Group type: COMPARATOR
Intervention: Standard drug group (multivitamin and local heat therapy)
Number of subjects: 29
Study 14710168 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional protein group (n=73) received 48.2 g/day additional protein.
Number of subjects: 148
Study 14710168 — intervention group
Group type: COMPARATOR
Intervention: Non-additional protein group (control).
Number of subjects: 148
Study 11208675 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-coated BX Velocity stents (slow release)
Number of subjects: 30
Study 11208675 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-coated BX Velocity stents (fast release)
Number of subjects: 30
Study 9258974 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of baclofen
Number of subjects: 0
Study 9258974 — intervention group
Group type: COMPARATOR
Intervention: Rectal administration of baclofen
Number of subjects: 0
Study 8435362 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin (EPI) 120 mg/m2 i.v. bolus injection divided over three days + Verapamil (VPL) 480 mg orally one day before and during EPI
Number of subjects: 51
Study 8435362 — intervention group
Group type: COMPARATOR
Intervention: Epirubicin (EPI) 120 mg/m2 i.v. bolus injection divided over three days without VPL
Number of subjects: 51
Study 3579676 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta administered intrathecally (IT)
Number of subjects: 69
Study 3579676 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 30328305 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber post placed in the palatal canal (Group 4)
Number of subjects: 50
Study 30328305 — intervention group
Group type: EXPERIMENTAL
Intervention: No post placed (Group 2)
Number of subjects: 50
Study 30328305 — intervention group
Group type: COMPARATOR
Intervention: Sound teeth with only metal crowns (Group 1)
Number of subjects: 50
Study 30328305 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber post placed in both buccal and palatal canals (Group 5)
Number of subjects: 50
Study 26970712 — intervention group
Group type: EXPERIMENTAL
Intervention: Androstadienone (ANDR)
Number of subjects: 46
Study 26970712 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 26970712 — intervention group
Group type: EXPERIMENTAL
Intervention: Androstadienone (ANDR) during stress
Number of subjects: 46
Study 24895301 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fluence Q-switched Nd:YAG laser (1,064 nm)
Number of subjects: 20
Study 24895301 — intervention group
Group type: COMPARATOR
Intervention: Low-fluence Q-switched alexandrite laser (755 nm)
Number of subjects: 20
Study 23364390 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 50 μg bid (FP100)
Number of subjects: 21
Study 23364390 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 250 μg bid (FP500)
Number of subjects: 21
Study 23364390 — intervention group
Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 21
Study 20385870 — intervention group
Group type: EXPERIMENTAL
Intervention: ST-246 250 mg/day
Number of subjects: 0
Study 20385870 — intervention group
Group type: EXPERIMENTAL
Intervention: ST-246 400 mg/day
Number of subjects: 0
Study 20385870 — intervention group
Group type: EXPERIMENTAL
Intervention: ST-246 800 mg/day
Number of subjects: 0
Study 20385870 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19112496 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorproguanil-dapsone+artesunate (CD+A)
Number of subjects: 702
Study 19112496 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine+sulphadoxine-pyrimethamine (AQ+SP)
Number of subjects: 702
Study 15821091 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonverbal task examining understanding of true or false beliefs
Number of subjects: 0
Study 12910336 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-phased carers' intervention comprising family sessions followed by relatives' groups
Number of subjects: 0
Study 12910336 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 10567284 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial chordal preservation (posterior leaflet only)
Number of subjects: 50
Study 10567284 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete chordal preservation (all chordal structures)
Number of subjects: 50
Study 10567284 — intervention group
Group type: COMPARATOR
Intervention: Mitral valve repair (comparison group)
Number of subjects: 50
Study 8921659 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass ionomer cement (AquaCem, De Trey)
Number of subjects: 60
Study 8921659 — intervention group
Group type: COMPARATOR
Intervention: Acrylic resin (Unite, Unitek Corp.)
Number of subjects: 60
Study 8921659 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass ionomer cement (AquaCem, De Trey) with cut groove base (DynaLock, Unitek)
Number of subjects: 60
Study 8921659 — intervention group
Group type: COMPARATOR
Intervention: Acrylic resin (Unite, Unitek Corp.) with cut groove base (DynaLock, Unitek)
Number of subjects: 60
Study 8921659 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass ionomer cement (AquaCem, De Trey) with meshed foil base (Unitwin, Unitek)
Number of subjects: 60
Study 8921659 — intervention group
Group type: COMPARATOR
Intervention: Acrylic resin (Unite, Unitek Corp.) with meshed foil base (Unitwin, Unitek)
Number of subjects: 60
Study 1832291 — intervention group
Group type: EXPERIMENTAL
Intervention: xipamide 20 mg once daily
Number of subjects: 12
Study 1832291 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 6391928 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen 1000 mg in the morning, placebo in the evening
Number of subjects: 48
Study 6391928 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen 1000 mg in the evening, placebo in the morning
Number of subjects: 48
Study 6391928 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg in the morning and 500 mg in the evening
Number of subjects: 48
Study 6391928 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 31654497 — intervention group
Group type: COMPARATOR
Intervention: Standard epithelium-off cross-linking (SCXL)
Number of subjects: 271
Study 31654497 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated epithelium-off cross-linking (ACXL)
Number of subjects: 271
Study 31654497 — intervention group
Group type: EXPERIMENTAL
Intervention: Transepithelial epithelium-on cross-linking (TCXL)
Number of subjects: 271
Study 31383465 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal antibiotic irrigation (polymyxin B, 500,000 units/L)
Number of subjects: 190
Study 31383465 — intervention group
Group type: COMPARATOR
Intervention: 0.9% NaCl irrigation (saline)
Number of subjects: 190
Study 29215302 — intervention group
Group type: EXPERIMENTAL
Intervention: Xing Qi Hua Ying Tang (XQHYT)
Number of subjects: 72
Study 29215302 — intervention group
Group type: COMPARATOR
Intervention: Hai Zao Yu Hu Tang (Control)
Number of subjects: 72
Study 27881530 — intervention group
Group type: EXPERIMENTAL
Intervention: Menstrual cups
Number of subjects: 751
Study 27881530 — intervention group
Group type: EXPERIMENTAL
Intervention: Sanitary pads
Number of subjects: 751
Study 27881530 — intervention group
Group type: COMPARATOR
Intervention: Usual practice control
Number of subjects: 751
Study 26149170 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg of bevacizumab
Number of subjects: 246
Study 26149170 — intervention group
Group type: COMPARATOR
Intervention: 0.5 mg of ranibizumab
Number of subjects: 246
Study 22790501 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthodontic manual toothbrush
Number of subjects: 64
Study 22790501 — intervention group
Group type: COMPARATOR
Intervention: Conventional manual toothbrush
Number of subjects: 64
Study 20156032 — intervention group
Group type: EXPERIMENTAL
Intervention: P-OM3 4 g/day + simvastatin 40 mg/day
Number of subjects: 0
Study 20156032 — intervention group
Group type: COMPARATOR
Intervention: Placebo + simvastatin 40 mg/day
Number of subjects: 0
Study 20156032 — intervention group
Group type: EXPERIMENTAL
Intervention: Total population (combined Non-switcher + Switcher)
Number of subjects: 0
Study 18587307 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine with 1:100.000 adrenaline (control)
Number of subjects: 84
Study 18587307 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% prilocaine with 0.30 IU felipressine
Number of subjects: 84
Study 18587307 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% mepivacaine with 1:100.000 adrenaline
Number of subjects: 84
Study 18587307 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% articaine with 1:100.100 adrenaline
Number of subjects: 84
Study 18587307 — intervention group
Group type: EXPERIMENTAL
Intervention: All anesthetics studied
Number of subjects: 84
Study 18587307 — intervention group
Group type: EXPERIMENTAL
Intervention: All anesthetics compared to lidocaine
Number of subjects: 84
Study 18587307 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of systolic blood pressure, diastolic blood pressure and heart rate
Number of subjects: 84
Study 15687321 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg L-000845704 once daily (qd)
Number of subjects: 227
Study 15687321 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg L-000845704 once daily (qd)
Number of subjects: 227
Study 15687321 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg L-000845704 twice daily (bid)
Number of subjects: 227
Study 15687321 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 227
Study 15687321 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of L-000845704
Number of subjects: 227
Study 11806644 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed Nd:YAG laser radiation at 200 mJ
Number of subjects: 114
Study 11806644 — intervention group
Group type: COMPARATOR
Intervention: Sodium hypochloride rinsing
Number of subjects: 114
Study 11806644 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed Nd:YAG laser radiation at 100 mJ
Number of subjects: 114
Study 10526807 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 40
Study 10526807 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 40
Study 10526807 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 8725495 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuronal cytoplasmic inclusions (NCIs) observed in the central nervous systems of patients with MSA
Number of subjects: 18
Study 8725495 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuronal cytoplasmic inclusions (NCIs)
Number of subjects: 18
Study 2025770 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression applied at 5 minutes
Number of subjects: 60
Study 2025770 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression applied immediately after injection
Number of subjects: 60
Study 2025770 — intervention group
Group type: COMPARATOR
Intervention: Compression applied after the 5 minute film
Number of subjects: 60
Study 6093528 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone (intramuscularly or intravenously)
Number of subjects: 2635
Study 6093528 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone (single dose of 250 mg)
Number of subjects: 2635
Study 6093528 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone (single dose)
Number of subjects: 2635
Study 31314045 — intervention group
Group type: EXPERIMENTAL
Intervention: iFR-guided treatment
Number of subjects: 2492
Study 31314045 — intervention group
Group type: COMPARATOR
Intervention: FFR-guided treatment
Number of subjects: 2492
Study 29877901 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented Reality (AR) application for improving functional vision
Number of subjects: 48
Study 29877901 — intervention group
Group type: COMPARATOR
Intervention: Control group (no AR application)
Number of subjects: 48
Study 27114196 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (50 mg, adjustable to 25 mg or 100 mg based on efficacy and safety)
Number of subjects: 11364
Study 27114196 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 11364
Study 27114196 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11364
Study 25699375 — intervention group
Group type: COMPARATOR
Intervention: Controlled Low Central Venous Pressure (LCVP)
Number of subjects: 60
Study 25699375 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute Normovolemic Hemodilution (ANH) + Controlled Low Central Venous Pressure (LCVP)
Number of subjects: 60
Study 22645995 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg estriol as vaginal cream
Number of subjects: 87
Study 22645995 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prophylactic treatment)
Number of subjects: 87
Study 20653966 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led education (weekly educational programs for one month)
Number of subjects: 99
Study 20653966 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 99
Study 20969443 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) using an InGaAlP diode laser, emitting light at 660 nm, 40 mW, and 4 J/cm².
Number of subjects: 42
Study 20969443 — intervention group
Group type: COMPARATOR
Intervention: Control group (no LLLT treatment).
Number of subjects: 42
Study 15607123 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (50 microg, b.i.d)
Number of subjects: 0
Study 15607123 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12296593 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolder bar attachment
Number of subjects: 36
Study 12296593 — intervention group
Group type: COMPARATOR
Intervention: Ball attachment
Number of subjects: 36
Study 9725475 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release amitriptyline formulation
Number of subjects: 0
Study 8067694 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil (1000 mg/m2 B.S.A. x 5 days) and Mitomycin‐C (14 mg/m2 B.S.A. 6 week intervals)
Number of subjects: 77
Study 8067694 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil (750 mg/m2 B.S.A. x 5 days) and a‐Interferon (5 miu/m2 B.S.A. daily x 5 then 3 times a week (TIW))
Number of subjects: 77
Study 8067694 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil (500 mg/m2 B.S.A. x 5 days), a‐Interferon (5 miu/m2 B.S.A. x 5 days then TIW) and 13‐Cis Retinoic Acid in escalating doses daily
Number of subjects: 77
Study 3289132 — intervention group
Group type: EXPERIMENTAL
Intervention: Early secondary suture combined with cefuroxime and metronidazole given intravenously
Number of subjects: 0
Study 3289132 — intervention group
Group type: COMPARATOR
Intervention: Healing by second intention
Number of subjects: 0
Study 29733447 — intervention group
Group type: EXPERIMENTAL
Intervention: Verinurad 10 mg + Allopurinol 300 mg
Number of subjects: 0
Study 29733447 — intervention group
Group type: EXPERIMENTAL
Intervention: Verinurad 10 mg
Number of subjects: 0
Study 29733447 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol 300 mg
Number of subjects: 0
Study 29733447 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine 0.6 mg
Number of subjects: 0
Study 29733447 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Verinurad and Allopurinol
Number of subjects: 0
Study 26586860 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified group-based vestibular rehabilitation (VR) intervention consisting of group sessions, individually modified VR exercises, a home exercise program, and an exercise diary over 8 weeks.
Number of subjects: 4
Study 26586860 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified group-based vestibular rehabilitation (VR) intervention
Number of subjects: 4
Study 25641452 — intervention group
Group type: COMPARATOR
Intervention: Transrectal (TR) 14-core biopsy
Number of subjects: 108
Study 25641452 — intervention group
Group type: EXPERIMENTAL
Intervention: Transperineal (TP) 14-core biopsy
Number of subjects: 108
Study 23653013 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone treatment (intra-muscular testosterone administered every 14 days to achieve BT levels 70-270 ng/dL)
Number of subjects: 29
Study 23653013 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sesame seed oil administered every 14 days)
Number of subjects: 29
Study 20439641 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab maintenance treatment (375 mg/m² intravenously once every 3 months)
Number of subjects: 465
Study 20439641 — intervention group
Group type: COMPARATOR
Intervention: Observation (control group)
Number of subjects: 465
Study 20439641 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab maintenance treatment
Number of subjects: 465
Study 18439225 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency (RF) exposure
Number of subjects: 17
Study 18439225 — intervention group
Group type: COMPARATOR
Intervention: Sham exposure
Number of subjects: 17
Study 16174118 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine treatment
Number of subjects: 37
Study 16174118 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 37
Study 16295040 — intervention group
Group type: EXPERIMENTAL
Intervention: HS-1 (Barrier Cream)
Number of subjects: 192
Study 16295040 — intervention group
Group type: EXPERIMENTAL
Intervention: HS-2 (Barrier Cream)
Number of subjects: 192
Study 16295040 — intervention group
Group type: COMPARATOR
Intervention: HP-1 (Skin Care Product)
Number of subjects: 192
Study 16295040 — intervention group
Group type: COMPARATOR
Intervention: HP-2 (Skin Care Product)
Number of subjects: 192
Study 16295040 — intervention group
Group type: COMPARATOR
Intervention: TEWL measurement for HP-1 vs HS-1
Number of subjects: 192
Study 16295040 — intervention group
Group type: COMPARATOR
Intervention: TEWL measurement for HP-2 vs HS-2
Number of subjects: 192
Study 10756492 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg buserelin (BSRL) stimulation (PCOD group P-1, n = 31)
Number of subjects: 43
Study 10756492 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg buserelin (BSRL) stimulation (PCOD group P-0.1, n = 12)
Number of subjects: 43
Study 10756492 — intervention group
Group type: COMPARATOR
Intervention: Control group C-1 (n = 12)
Number of subjects: 43
Study 10756492 — intervention group
Group type: COMPARATOR
Intervention: Control group C-0.1 (n = 11)
Number of subjects: 43
Study 8951253 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency ventilation (HFV)
Number of subjects: 9
Study 8951253 — intervention group
Group type: COMPARATOR
Intervention: Conventional ventilation
Number of subjects: 9
Study 1504957 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical Strip (VS) palpation technique
Number of subjects: 34
Study 1504957 — intervention group
Group type: COMPARATOR
Intervention: Concentric Circle (CC) palpation technique
Number of subjects: 34
Study 6388898 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous recombinant human tissue-type plasminogen activator (rt-PA) at a dosage of 0.5 to 0.75 mg/kg over 30 to 120 min.
Number of subjects: 45
Study 6388898 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 6388898 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary rt-PA (after crossover from placebo)
Number of subjects: 45
Study 6388898 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary streptokinase (after unresponsive rt-PA treatment)
Number of subjects: 45
Study 6388898 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous rt-PA
Number of subjects: 45
Study 31621670 — intervention group
Group type: EXPERIMENTAL
Intervention: Airtraq video laryngoscope
Number of subjects: 70
Study 31621670 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 70
Study 29738412 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral conjugated equine estrogen (oCEE)
Number of subjects: 100
Study 29738412 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal 17β‐estradiol (tE2)
Number of subjects: 100
Study 29738412 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 29738412 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (oCEE and tE2 combined)
Number of subjects: 100
Study 26994987 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabies + JE-Accelerated
Number of subjects: 661
Study 26994987 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabies + JE-Conventional
Number of subjects: 661